• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤浸润淋巴细胞(TILs)与导管癌后二次乳腺事件风险

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma .

作者信息

Farolfi Alberto, Petracci Elisabetta, Serra Luigi, Ravaioli Alessandra, Bravaccini Sara, Ravaioli Sara, Tumedei Maria Maddalena, Ulivi Paola, Canale Matteo, Puccetti Maurizio, Falcini Fabio, Folli Secondo, Curcio Annalisa, Rocca Andrea

机构信息

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

出版信息

Front Oncol. 2020 Aug 19;10:1486. doi: 10.3389/fonc.2020.01486. eCollection 2020.

DOI:10.3389/fonc.2020.01486
PMID:32974178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7466557/
Abstract

Women with a diagnosis of ductal carcinoma (DCIS) have a high risk of developing a second breast event (SBE). The immune system might play a role in trying to prevent a SBE. Patients diagnosed with DCIS were identified in the population-based cancer registry of Area Vasta Romagna from 1997 to 2010. Median follow-up is 8.5 years. Tumor-infiltrating lymphocytes (TILs) were evaluated both in index DCIS and in SBE. The main endpoint was to assess the association between TILs' levels in index DCIS and risk of a SBE. Out of 496 DCIS patients, 100 SBEs (20.2%) were identified: 55 ipsilateral (11.1%) and 43 contralateral (8.7%). The distribution of TILs was heterogeneous, but significantly associated with grade, necrosis, screen detection and type of surgery. Patients stratified according to TILs percentage (≤5% and >5%) did not show a statistically significant difference in the 5-year cumulative incidence of SBEs: 14.9% (95% CI 11.3-19.1) and 11.0% (95% CI, 6.9-16.2), respectively ( = 0.147). In the subgroup of patients who did not receive radiotherapy, TILs >5% were associated with a reduced risk of SBE (HR 0.34, 95% CI 0.14-0.82, = 0.016). Although we did not find any significant association between TILs and SBE, further studies evaluating their role according to radiotherapy are warranted.

摘要

被诊断为导管原位癌(DCIS)的女性发生第二次乳腺事件(SBE)的风险很高。免疫系统可能在试图预防SBE中发挥作用。1997年至2010年期间,在大区瓦萨罗马涅基于人群的癌症登记处中识别出被诊断为DCIS的患者。中位随访时间为8.5年。对原发性DCIS和SBE中的肿瘤浸润淋巴细胞(TILs)进行了评估。主要终点是评估原发性DCIS中TILs水平与SBE风险之间的关联。在496例DCIS患者中,识别出100例SBE(20.2%):55例同侧(11.1%)和43例对侧(8.7%)。TILs的分布是异质性的,但与分级、坏死、筛查发现和手术类型显著相关。根据TILs百分比(≤5%和>5%)分层的患者在SBE的5年累积发病率上没有显示出统计学上的显著差异:分别为14.9%(95%CI 11.3 - 19.1)和11.0%(95%CI,6.9 - 16.2)(P = 0.147)。在未接受放疗的患者亚组中,TILs>5%与SBE风险降低相关(HR 0.34,95%CI 0.14 - 0.82,P = 0.016)。尽管我们没有发现TILs与SBE之间有任何显著关联,但有必要进一步研究根据放疗评估它们的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/11aff6785e94/fonc-10-01486-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/6d44404fa501/fonc-10-01486-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/c31e0894a75a/fonc-10-01486-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/1c05164c0e84/fonc-10-01486-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/11aff6785e94/fonc-10-01486-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/6d44404fa501/fonc-10-01486-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/c31e0894a75a/fonc-10-01486-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/1c05164c0e84/fonc-10-01486-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c98a/7466557/11aff6785e94/fonc-10-01486-g0004.jpg

相似文献

1
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma .肿瘤浸润淋巴细胞(TILs)与导管癌后二次乳腺事件风险
Front Oncol. 2020 Aug 19;10:1486. doi: 10.3389/fonc.2020.01486. eCollection 2020.
2
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.乳腺导管原位癌中肿瘤浸润淋巴细胞(TILs)的流行率和临床相关性。
Ann Oncol. 2017 Feb 1;28(2):321-328. doi: 10.1093/annonc/mdw623.
3
Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ.治疗导管原位癌保乳手术后的第二乳房事件。
J Natl Compr Canc Netw. 2018 Apr;16(4):387-394. doi: 10.6004/jnccn.2018.7003.
4
Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).肿瘤浸润淋巴细胞在当代女性导管原位癌(DCIS)队列中的作用。
Ann Surg Oncol. 2019 Oct;26(10):3337-3343. doi: 10.1245/s10434-019-07562-x. Epub 2019 Jun 25.
5
Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.肿瘤浸润淋巴细胞为低风险导管原位癌患者增加预后信息:来自瑞典导管原位癌随机放疗试验的结果
Eur J Cancer. 2022 Jun;168:128-137. doi: 10.1016/j.ejca.2022.01.016. Epub 2022 Feb 27.
6
Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.肿瘤浸润淋巴细胞在 DCIS 中的预后价值:一项荟萃分析。
BMC Cancer. 2022 Jul 18;22(1):782. doi: 10.1186/s12885-022-09883-9.
7
Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.肿瘤浸润淋巴细胞对导管原位癌的预后及预测意义
Oncoimmunology. 2021 Mar 18;10(1):1875637. doi: 10.1080/2162402X.2021.1875637.
8
Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.多国原位导管癌(DCIS)队列中的肿瘤浸润淋巴细胞。
Cancers (Basel). 2022 Aug 13;14(16):3916. doi: 10.3390/cancers14163916.
9
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.肿瘤浸润淋巴细胞分析揭示了原位乳腺导管癌的两个新的生物学不同亚群。
BMC Cancer. 2018 Feb 3;18(1):129. doi: 10.1186/s12885-018-4013-6.
10
Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial.保乳手术后放疗的效果取决于肿瘤浸润淋巴细胞的存在:SweBCG91RT 随机试验的长期随访结果。
J Clin Oncol. 2019 May 10;37(14):1179-1187. doi: 10.1200/JCO.18.02157. Epub 2019 Apr 2.

引用本文的文献

1
Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights.解码导管原位癌中肿瘤浸润淋巴细胞的异质性:免疫微环境动态及预后见解
Discov Oncol. 2025 Jul 28;16(1):1435. doi: 10.1007/s12672-025-03288-3.
2
From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment.从导管原位癌到浸润性乳腺癌:细胞外微环境的预后价值
J Exp Clin Cancer Res. 2024 Dec 23;43(1):329. doi: 10.1186/s13046-024-03236-z.
3
Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast.

本文引用的文献

1
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.肿瘤浸润淋巴细胞与预后:早期三阴性乳腺癌患者的汇总分析。
J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.
2
Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.宫颈癌新辅助化疗前后肿瘤浸润性CD8 +和FOXP3 +淋巴细胞
Diagn Pathol. 2018 Nov 24;13(1):93. doi: 10.1186/s13000-018-0770-4.
3
Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
乳腺癌导管原位癌(DCIS)术后复发和转移的检测。
Histopathology. 2023 Jan;82(1):106-118. doi: 10.1111/his.14804.
4
Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.多国原位导管癌(DCIS)队列中的肿瘤浸润淋巴细胞。
Cancers (Basel). 2022 Aug 13;14(16):3916. doi: 10.3390/cancers14163916.
5
Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx Digital Spatial Profiler.使用空间高多重技术进行免疫分析的挑战与机遇:NanoString GeoMx数字空间分析系统
Front Oncol. 2022 Jun 29;12:890410. doi: 10.3389/fonc.2022.890410. eCollection 2022.
6
Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis.肿瘤浸润淋巴细胞在 DCIS 中的预后价值:一项荟萃分析。
BMC Cancer. 2022 Jul 18;22(1):782. doi: 10.1186/s12885-022-09883-9.
7
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.对导管原位癌免疫微环境进行全面的免疫谱分析,以评估其对同侧浸润性乳腺癌风险的影响。
Br J Cancer. 2022 Oct;127(7):1201-1213. doi: 10.1038/s41416-022-01888-2. Epub 2022 Jun 29.
8
Prognostic Score System Using Preoperative Inflammatory, Nutritional and Tumor Markers to Predict Prognosis for Gastric Cancer: A Two-Center Cohort Study.基于术前炎症、营养和肿瘤标志物的预后评分系统预测胃癌预后:一项两中心队列研究。
Adv Ther. 2021 Sep;38(9):4917-4934. doi: 10.1007/s12325-021-01870-z. Epub 2021 Aug 11.
9938 例女性筛检性乳腺导管原位癌的管理和 5 年结果:英国 Sloane 项目。
Eur J Cancer. 2018 Sep;101:210-219. doi: 10.1016/j.ejca.2018.06.027. Epub 2018 Aug 6.
4
Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.肿瘤浸润淋巴细胞对乳腺导管原位癌的预后意义。
Mod Pathol. 2018 Aug;31(8):1226-1236. doi: 10.1038/s41379-018-0040-8. Epub 2018 Mar 20.
5
Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.局部晚期直肠癌术前放疗的肿瘤淋巴细胞免疫反应:LYMPHOREC研究。
Oncoimmunology. 2017 Nov 27;7(3):e1396402. doi: 10.1080/2162402X.2017.1396402. eCollection 2018.
6
Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.未切除的导管原位癌发展为浸润性癌的危险因素。
Eur J Surg Oncol. 2018 Apr;44(4):429-435. doi: 10.1016/j.ejso.2017.12.007. Epub 2018 Jan 11.
7
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.肿瘤浸润淋巴细胞分析揭示了原位乳腺导管癌的两个新的生物学不同亚群。
BMC Cancer. 2018 Feb 3;18(1):129. doi: 10.1186/s12885-018-4013-6.
8
Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer.新辅助放化疗可减少直肠癌中肿瘤浸润淋巴细胞的总量,但会增加CD8⁺/颗粒酶B⁺(GrzB)细胞毒性T细胞的数量。
Oncoimmunology. 2017 Nov 7;7(2):e1393133. doi: 10.1080/2162402X.2017.1393133. eCollection 2018.
9
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.浸润淋巴细胞与不同亚型乳腺癌患者预后的关系:新辅助化疗治疗 3771 例患者的汇总分析
Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.
10
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.评估实体瘤中的肿瘤浸润淋巴细胞:病理学家实用综述及国际免疫肿瘤生物标志物工作组提出的标准化方法建议:第 1 部分:评估宿主免疫反应、浸润性乳腺癌及导管原位癌中的肿瘤浸润淋巴细胞、转移性肿瘤沉积及进一步研究领域。
Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162.